FEN yields 7.50% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, FEN + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FEN + JNJ for your $10,000?
First Trust Energy Income and Growth Fund is a closed-ended equity mutual fund launched and managed by First Trust Advisors L.P. It is co-managed by Energy Income Partners, LLC. The fund invests in the public equity markets of the United States. It seeks to invest in stocks of companies operating in the energy sector, including companies in the business of transporting, processing, storing, distributing, or marketing natural gas, natural gas liquids (including propane), crude oil, refined petroleum products, coal or electricity, or exploring, developing, managing or producing such commodities or products, or in supplying energy-related products and services. The fund primarily invests in growth stocks of companies, energy sector MLPs, and MLP-related entities. It employs a combination of fundamental and quantitative analysis, focusing on such factors as debt to cash flows, coverage ratios, incentive structure, management team, track record of distribution, and dividend growth to create its portfolio. The fund benchmarks the performance of its portfolio against the S&P 500 Index, Barclays Capital U.S. Credit Index of Corporate Bonds, Alerian MLP Total Return Index, Wells Fargo Midstream MLP Total Return Index, and composite index comprised of 50% Alerian MLP Total Return Index and 50% Wells Fargo Midstream MLP Total Return Index. It was formerly known as Energy Income & Growth Fund. First Trust Energy Income and Growth Fund was formed on March 25, 2004 and is domiciled in the United States.
Full FEN Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.